The poor experience of the HTA Review was predictable and predicted. While, in many ways, it might be too late to correct, there are valuable lessons that can guide advocacy over the years ahead. The primary lesson is prioritising caution over misplaced and frankly naive enthusiasm for controlled processes run by the all-powerful single-payer.
The process looked like a teddy bear, but a closer look has revealed a hidden risk
March 11, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Immutep posts encouraging Phase 2 results as 'Efti' spurs robust anti-tumour activity
November 13, 2025 - - Australian Biotech -
PYC Therapeutics appoints Peter Coleman as new Chair as part of board renewal
November 13, 2025 - - Australian Biotech -
New gene discoveries improve diagnosis of inherited heart disease
November 13, 2025 - - Australian Biotech -
Chimeric Therapeutics reports strong early results from CHM CDH17 Phase 1/2 trial
November 13, 2025 - - Australian Biotech -
Australia joins global WHO task force to tackle antimicrobial resistance
November 13, 2025 - - Latest News -
New post-market review workplan focuses on real-world data and patient outcomes
November 13, 2025 - - Latest News -
Government adds new first-line treatment to the PBS for deadly blood cancer
November 13, 2025 -
